The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.
A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...
Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...
A YOUNG mum battling a rare form of cancer passed away surrounded by loved ones after suffering complications from treatment.
Cutaneous chronic graft-versus-host disease reduces quality of life through skin symptoms and broader impacts, guiding ...
Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...
CARsgen’s allogeneic CD38 CAR-T therapy administers first dose in an investigator-initiated trial: Shanghai, China Tuesday, January 21, 2025, 18:00 Hrs [IST] CARsgen Therapeutic ...
French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 ...
Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...
Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.
Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback